195 related articles for article (PubMed ID: 27306290)
1. Inhibitory PARP w terapii raka jajnika.
Kruczała MA; Grela-Wojewoda A; Cedrych I
Ginekol Pol; 2016; 87(2):131-4. PubMed ID: 27306290
[TBL] [Abstract][Full Text] [Related]
2. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
3. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
7. PARP inhibition in recurrent ovarian cancer.
Moore KN; Pothuri B; Monk B; Coleman RL
Clin Adv Hematol Oncol; 2020 Oct; 18(10):647-655. PubMed ID: 33201871
[TBL] [Abstract][Full Text] [Related]
8. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
[TBL] [Abstract][Full Text] [Related]
9. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
[TBL] [Abstract][Full Text] [Related]
13. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
Al Hadidi S; Aburahma A; Badami S; Upadhaya S
Oncol Res Treat; 2018; 41(4):226-235. PubMed ID: 29562224
[No Abstract] [Full Text] [Related]
14. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Kurnit KC; Avila M; Hinchcliff EM; Coleman RL; Westin SN
Pharmacol Ther; 2020 Sep; 213():107588. PubMed ID: 32450190
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors for the Treatment of Ovarian Cancer.
Cortesi L; Toss A; Cucinotto I
Curr Cancer Drug Targets; 2018; 18(9):877-893. PubMed ID: 29521233
[TBL] [Abstract][Full Text] [Related]
18. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition: A promising therapeutic target in ovarian cancer.
Musella A; Marchetti C; Gasparri ML; Salerno L; Casorelli A; Domenici L; Imperiale L; Ruscito I; Abdul Halim T; Palaia I; Di Donato V; Pecorini F; Monti M; Muzii L; Panici PB
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):44-61. PubMed ID: 26518896
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
